Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

GlobeNewswire November 4, 2024

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

GlobeNewswire October 22, 2024

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

GlobeNewswire October 21, 2024

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

GlobeNewswire October 18, 2024

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

GlobeNewswire October 3, 2024

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

GlobeNewswire August 7, 2024

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

GlobeNewswire July 31, 2024

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

GlobeNewswire June 14, 2024

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

GlobeNewswire June 14, 2024

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

GlobeNewswire May 14, 2024

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 10, 2024

Editas Medicine Announces First Quarter 2024 Results and Business Updates

GlobeNewswire May 8, 2024

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

GlobeNewswire May 2, 2024

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

GlobeNewswire May 1, 2024

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire April 22, 2024

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

GlobeNewswire February 28, 2024

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

GlobeNewswire February 21, 2024

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire January 31, 2024